Disease-Modifying Agents for Multiple Sclerosis-Reference-Cited by-同舟云学术

Disease-Modifying Agents for Multiple Sclerosis

Published:2008 Issue:17 Volume:68 Page:2445-2468
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Menge Til,Weber Martin S,Hemmer Bernhard,Kieseier Bernd C,von Büdingen Hans-Christian,Warnke Clemens,Zamvil Scott S,Boster Aaron,Khan Omar,Hartung Hans-Peter,Stüve Olaf

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Reference259 articles.

1. Multiple sclerosis in 54 twinships: Concordance rate is independent of zygosity

2. Multiple Sclerosis

3. Multiple Sclerosis — The Plaque and Its Pathogenesis

4. Multiple sclerosis

5. Clinical characteristics of progressive relapsing multiple sclerosis

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses;Proceedings of the National Academy of Sciences;2024-01-24

2. Astrocytic TIMP-1 regulates production of Anastellin, a novel inhibitor of oligodendrocyte differentiation and FTY720 responses;2023-02-18

3. FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury;Frontiers in Immunology;2020-06-23

4. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2019-07

5. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study;Multiple Sclerosis and Related Disorders;2019-05